VOLUME 18 | NUMBER 9 | SEPTEMBER 2012 nature medicine a r t i c l e s HSCs exist in a quiescent state in the bone marrow niche and are the source of all hematological progenitors and differentiated cells throughout the lifespan of an organism [1] [2] [3] [4] [5] [6] . One of the central tasks of stem-cell biology is to define the modes and mechanisms that regulate the self-renewal and commitment of stem cells, as alterations in this equilibrium have a substantial effect on hematopoietic homeostasis and maintenance. It has been suggested that asymmetric division of HSCs ensures that a fraction of daughter cells retain features of stem cells while replenishing the committed compartment of hematopoietic progenitors [7] [8] [9] [10] . Therefore, identifying the factors that regulate this process would be of great biological and therapeutic relevance.
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HSCs exist in a quiescent state in the bone marrow niche and are the source of all hematological progenitors and differentiated cells throughout the lifespan of an organism [1] [2] [3] [4] [5] [6] . One of the central tasks of stem-cell biology is to define the modes and mechanisms that regulate the self-renewal and commitment of stem cells, as alterations in this equilibrium have a substantial effect on hematopoietic homeostasis and maintenance. It has been suggested that asymmetric division of HSCs ensures that a fraction of daughter cells retain features of stem cells while replenishing the committed compartment of hematopoietic progenitors [7] [8] [9] [10] . Therefore, identifying the factors that regulate this process would be of great biological and therapeutic relevance.
PPARs, such as PPAR-α, PPAR-δ (also known as PPAR-β) and PPAR-γ (encoded by PPARA, PPARD and PPARG, respectively) are members of the nuclear receptor superfamily of transcription factors that control nutrient sensing and the transcriptional regulation of metabolic pathways 11 , especially fatty-acid transport and FAO 12, 13 . Activators and inhibitors of these pathways have been developed, and PPAR agonists have been tested in the treatment of obesity and metabolic disorders 14, 15 .
The PML (promyelocytic leukemia) tumor-suppressor gene, originally cloned at the break point of the t(15;17) chromosomal translocation of acute promyelocytic leukemia, has a key role in the maintenance of HSCs 16 . The PML protein is the essential component of PML nuclear bodies, which are subnuclear structures implicated in a wide variety of processes, including post-translational modifications and transcriptional regulation 17 . How PML exerts its crucial function in the biology and maintenance of HSCs has not been established.
Over the past few years, a better understanding has developed of the relationship between HSC function and metabolism [18] [19] [20] [21] [22] . Recent studies have focused largely on glycolysis and energy homeostasis; however, the contribution of lipid catabolism to HSC maintenance has not been defined. Here we identify a previously unknown PPAR-FAO pathway that is crucial to the maintenance of HSCs and the control of asymmetric cell division. Moreover, we place this metabolic pathway downstream of PML, which can be viewed as a fine-tuning rheostat that is essential for HSC maintenance. These findings have straightforward therapeutic implications for the improvement of both the efficacy of bone marrow transplantation (BMT) and the treatment of hematological malignancies.
RESULTS

PPAR-d has a central role in HSC maintenance
The contribution of lipid catabolism to HSC function has not been defined. As PPARs have been established as crucial regulators of the transcriptional program underlying FAO, we investigated whether PPAR and FAO could be relevant to HSC biology.
We first analyzed the expression of PPAR family members in CD34 − c-Kit + Sca + Lin − (KSL) cells from wild-type (WT) mice and found that PPAR-δ was the predominantly expressed receptor ( Supplementary  Fig. 1a,b) . We next assessed whether PPAR-δ function has a role in the maintenance of HSCs. We conditionally deleted Ppard in KSL mouse bone marrow cells ex vivo by retroviral Cre transduction and sorting of GFP + retrovirally infected cells to evaluate the characteristics of Ppard-deleted HSCs (Fig. 1a) . We initially investigated the function of Ppard-deleted HSCs in vivo in BMT experiments using GFP + KSL cells. Loss of Ppard did not affect the homing of the HSCs after BMT (Fig. 1b and Supplementary Fig. 1c ) but did markedly affect their long-term repopulating capacity (Fig. 1c,d and Supplementary Fig. 1d ). We found further evidence of the defective repopulating capacity of Ppard-deleted HSCs in the second and third rounds of serial BMT (Fig. 1e,f) . We found no clear differences in the expression of genes previously described to be involved in the maintenance of the HSC compartment in Ppard-deleted HSCs (Supplementary Fig. 1e ).
Consistent with these data, deletion of Ppard also led to a marked decrease in the function of the HSCs in vitro, with reduced numbers of cobblestone area-forming cells (CAFCs), a surrogate indicator of HSC maintenance (Supplementary Fig. 1f ) 23 and colony-forming ability in long-term culture (defined as the cells' long-term culture initiating cell (LTC-IC) capacity (Supplementary Fig. 1g-i) ), together with a marked reduction in ATP levels (Supplementary Fig. 1j ). Cre expression itself did not have significant effects on the proliferation and differentiation of the stem or progenitor cells in in vitro colony assays (Supplementary Fig. 1k ).
Several HSC regulatory factors modulate the exit of stem cells from quiescence 2, 6 . We therefore evaluated the relevance of PPAR-δ to the maintenance of a quiescent state. Notably, deletion of Ppard in CD150 + CD48 − KSL cells resulted in their exit from quiescence ( Fig. 1g and Supplementary Fig. 1l ).
PPAR-d activators enhance HSC function
We next tested whether pharmacological activation of PPAR-δ leads to increased HSC maintenance and function in vivo and in vitro. First, we treated 2-month-old mice with the PPAR-δ agonist GW-501516 by oral gavage daily for 28 days (Supplementary Fig. 2a ). This treatment did not alter the proliferation, differentiation or overall number of progenitor cells at steady state, although it did increase the LTC-IC capacity of the bone marrow cells (Supplementary Fig. 2b-d and data not shown).
We next administered two pharmacological activators of PPAR-δ at low doses in vitro to bone hematopoietic stem and progenitor cells (L-165,041 or GW-501516) [24] [25] [26] . Incubation with either of these activators increased cobblestone area formation ( Supplementary  Fig. 2e ), consistent with increased expression of PPAR-δ targets (Supplementary Fig. 2f ) and higher ATP levels ( Supplementary  Fig. 2g ). We also found that culturing CD34 − KSL cells in the presence of either of the PPAR-δ agonists increased the ability of these cells to generate colonies of differentiated hematopoietic cells in LTC-IC assays ( Supplementary Fig. 2h,i) .
To provide evidence of the potential benefit of PPAR-δ activators to HSC function, we investigated the effect of GW-501516 in BMT experiments. We transplanted 1.5 × 10 3 KSL cells into lethally irradiated mice and treated the recipient mice with vehicle or GW-501516 daily during the period of HSC homing, lodgement and engraftment to the bone marrow niche [27] [28] [29] (Fig. 2a) . Six weeks after transplantation, a time point at which there was a major contribution of the donor Fig. 2b and Supplementary Fig. 2j ). We obtained similar results when we administered GW-501516 for a shorter treatment period of 2 weeks (Supplementary Fig. 2k,l) . Notably, treatment of recipient mice with GW-501516 also significantly increased the longterm reconstitution capacity of bone marrow KSL cells and mononuclear cells in secondary transplantation experiments (Fig. 2c-e) .
To test whether PPAR-δ agonists exert their beneficial activity through the cell-autonomous activation of PPAR-δ in HSCs, we treated WT or Ppard-deleted CD34 − KSL cells with GW-501516. Ppard-deleted HSCs were refractory to the effect of GW-501516 in both CAFC and LTC-IC assays ( Supplementary Fig. 3a,b) . In addition, treatment of recipient mice with GW-501516 did not increase the repopulation capacity of Ppard-deleted KSL cells ( Fig. 2f and Supplementary Fig. 3c ). Furthermore, in vitro treatment of WT CD34 − KSL cells with GW-501516 was able to increase their function in the absence of stromal cells (Supplementary Fig. 4) .
Taken together, these data reveal PPAR-δ as a regulator of HSC maintenance and function whose activity can be modified pharmacologically and that acts in an HSC cell-autonomous manner.
Inhibition of mitochondrial FAO impairs HSC maintenance PPAR transcription factors are central regulators of nutrient sensing, metabolic reprogramming and differentiation 11 . In particular, PPAR-δ, together with PPAR-α, has crucial roles in the sensing of fatty acids and the activation of the FAO transcriptional program 13, 30 . We therefore evaluated the requirement of active FAO for HSC maintenance.
We first measured FAO in bone marrow undifferentiated and differentiated hematopoietic cells. KSL cells had detectable FAO, as determined by measuring 3 H-palmitate dehydrogenation in the presence or absence of a maximal dose (100 µM) of etomoxir, a pharmacological inhibitor of mitochondrial β-oxidation of long-chain fatty acids that does not affect the oxidation of shortchain fatty acids or peroxisomal FAO 31, 32 (Fig. 3a) . FAO was not detected using the same number of Lin + differentiated cells, as there was no statistically significant difference in the assay with or without etomoxir (Fig. 3a) . FAO analysis tested with up to 2.5-fold more Lin + cells yielded similar results (data not shown). This result is consistent with the finding that the levels of PPAR-δ target gene expression are reduced in the differentiated compartment ( Supplementary Fig. 5a ).
To further evaluate whether mitochondrial FAO has a role in HSC biology, we evaluated the effect of etomoxir on the ability of transplanted cells to repopulate the bone marrow. We did not find any toxic effect of etomoxir in our experimental settings ( Supplementary  Fig. 5c -e and data not shown), in line with previous reports 33 . A 4-week treatment of the recipient mice with etomoxir after BMT in lethally irradiated mice led to a significant reduction in the number of long-term HSCs in the bone marrow (Fig. 3b) . In addition, a shorter duration of etomoxir treatment (2 weeks) after BMT resulted in a substantial decrease in the number of long-term CD34 − Flt3 − KSL cells in the bone marrow and of donor-derived cells in peripheral blood 24 weeks after transplantation (Fig. 3c,d and Supplementary Fig. 5b ). Moreover, we observed a reduced reconstitution capacity of bone marrow cells in secondary BMT experiments in which the recipient mice were treated with etomoxir using two different protocols of serial BMT ( Fig. 3e-h) . Notably, both in vitro and in vivo, a 2-week treatment with the doses of etomoxir that we used in these experiments increased the number of total CD34 − KSL cells but did not affect cell survival or result in toxicity to these cells ( Supplementary Fig. 5c-e) . Note that etomoxir, similarly to other components of this pathway as shown below, had a biphasic effect, inducing a short-term expansion of HSCs, followed by the exhaustion of these cells ( Supplementary  Fig. 5c,d ,f-i).
We also analyzed the effect of mitochondrial FAO inhibition in vitro. Incubation of CD34 − KSL cells with etomoxir led to a reduction in Fig. 5f ). In the LTC-IC assay, etomoxir treatment triggered a response that was opposite to that observed with PPAR-δ activators. Similarly to the behavior of Ppard-deleted KSL cells in this assay, etomoxir treatment led to an initial expansion of hematopoietic stem and progenitor cells (in agreement with an increased exit from quiescence) followed by exhaustion of the compartment (Supplementary Fig. 5g-i) . Consistent with previous data ( Supplementary Figs. 1j and 2g) , treatment with etomoxir led to a reduction in the levels of ATP, in line with FAO inhibition (Supplementary Fig. 5j,k) . Notably, in vitro treatment of WT CD34 − KSL cells with etomoxir decreased their function in the absence of stromal cell coculture ( Supplementary Fig. 4 ).
To test whether the enhancement of HSC function mediated by PPAR-δ activation depends on mitochondrial FAO, we treated mononuclear cells (Supplementary Fig. 6a,c) and CD34 − KSL cells (Supplementary Fig. 6b,d ) in vitro as well as in WT mice in vivo (Supplementary Fig. 6e ) with GW-501516, etomoxir or both. We found that inhibition of mitochondrial FAO with etomoxir partially or completely prevented the beneficial effects of GW-501516 both in vitro (as assessed by CAFC and LTC-IC capacity) and in vivo (as assessed by Pyronin Y staining as a measure of HSC quiescence) ( Supplementary  Fig. 6a-e) . We also investigated whether the effects of etomoxir depend on PPAR-δ. Compared to treatment of WT HSCs, etomoxir had a reduced effect on Ppard-deleted cells on HSC maintenance (as assessed by in vitro LTC-IC capacity and in vivo repopulating capacity) and ATP levels ( Supplementary Fig. 6f-h) .
Taken together, these data uncover a role for FAO downstream of PPAR-δ in the regulation of HSC maintenance.
PPAR-d agonists rescue defective Pml −/− HSCs
We have previously shown that deletion of Pml results in loss of quiescence and maintenance of HSCs (Supplementary Fig. 7a,b) and, consequently, exhaustion of the HSC compartment 16 ( Supplementary  Fig. 7c,d ). Here we have found that Pml-deficient HSCs have lower expression of PPAR-δ targets compared to WT cells using either the gene encoding β-actin (Fig. 4a) or the gene 36b4 (data not shown) as the internal control. This observation, together with previous findings showing that PML regulates the activity of several transcriptional factors and cofactors 17 , led us to hypothesize that the regulation of PPAR signaling and FAO by PML in HSCs might be of relevance to their maintenance and that, in turn, the defect in maintenance in Pml-deleted HSCs could be rescued by pharmacologically enhancing PPAR-δ activity.
We first determined the contribution of PML to PPAR-δ signaling and FAO in hematopoietic cells. As stated above, PML-deficient HSCs had reduced expression of PPAR-δ targets (Fig. 4a) and reduced ATP levels (Supplementary Fig. 7e ). PML expression Fig. 7f) . Notably, Pml-deleted KSL cells had lower levels of FAO compared to WT cells (Fig. 4b) . However, there was no difference in FAO between Pml-deleted and WT Lin + differentiated cells (Supplementary Fig. 7g ), in agreement with the idea that PML expression is markedly reduced during the course of hematopoietic differentiation 16 . Taken together, these data suggest that PML regulates PPAR-δ signaling and FAO in HSCs. This data corroborates our observations showing that PML promotes PGC1A deacetylation, PPAR signaling activation and FAO in other cellular systems 35 . We next evaluated the contribution of PPAR-δ signaling to the maintenance defect observed in Pml-deleted HSCs. We first tested whether PPAR-δ activators administered systemically in vivo could rescue this maintenance defect. As previously reported 16, 36 , transplantation of Pml-deleted KSL cells with WT competitor cells into lethally irradiated mice led to the expansion and subsequent exhaustion of the Pml knockout HSC compartment (Fig. 4c-e and Supplementary  Fig. 8) . Notably, treatment of the recipient mice with GW-501516 for 14 d prevented the expansion phase and ameliorated the exhaustion of the Pml knockout HSC compartment (Supplementary Fig. 8a,b) . Consistent with these results, treatment with GW-501516 led to a significant recovery in the number of Pml-deleted HSCs in the bone marrow of the recipient mice (Fig. 4c-e and Supplementary   Fig. 8c-f) . In a secondary BMT experiment, a treatment duration as short as 2 weeks starting immediately after primary transplantation markedly increased the repopulating capacity of Pml-deleted HSCs in the bone marrow of the secondary recipient mice ( Supplementary  Fig. 8a,g-i) . Notably, a 4-week treatment of primary recipient mice with GW-501516 after transplantation with Pml-deleted KSL cells (Fig. 4c) rescued the number of CD150 + CD48 − CD41 − CD34 − Flt3 − KSL cells in the bone marrow measured 6 weeks after transplantation and also ameliorated the reconstitution defect of Pml-deleted cells in secondary transplantation experiments (Fig. 4d,e) .
In vitro, administration of either of the PPAR-δ activators GW-501516 or L-165,041 to CD34 − KSL cells increased cobblestone area formation to a greater extent in Pml-deleted cells than in WT CD34 − KSL cells (Fig. 4f, Supplementary Fig. 9a and data not shown; GW-501516: 1.4-fold in WT compared to 3.5-fold in Pml-deleted cells; L-165,041: 1.6-fold in WT compared to 2.4-fold in Pml-deleted cells). GW-501516 treatment of Pml knockout CD34 − KSL cells also led to a recovery in PPAR-δ signaling (Supplementary Fig. 9b ) and in ATP levels (Supplementary Fig. 9c) a r t i c l e s normalized both the expansion and the subsequent exhaustion phases of Pml-deleted CD34 − KSL cells, as determined by LTC-IC assays in vitro ( Fig. 4g and Supplementary Figs. 7a,b and 9d) . These data collectively show that the maintenance defect of Pml-deleted HSCs arises, at least in part, from dysfunctional PPAR-δ signaling and FAO.
Pml loss results in PPAR-d-dependent loss of asymmetric division
We next asked what molecular mechanism was responsible for the effect of PML-PPAR-δ-FAO pathway modulation on HSC maintenance. Asymmetric cell division has recently been suggested to regulate cellfate decisions in the mammalian hematopoietic system, with crucial roles in stem-cell renewal 7 . Therefore, we hypothesized that PML regulation of PPAR-δ signaling and FAO may be essential for asymmetric division.
We studied the symmetry of cell divisions using a binary assay that takes advantage of two surface markers, Tie2 and CD48 (refs. 2,37) . In a purified CD150 + CD48 − CD41 − Flt3 − CD34 − KSL cell population from WT mice, we observed Tie2 positivity in up to 90% of the cells (Fig. 5a) . In single-cell culture assays, after the first cell division, more than 40% of these cells divided to give rise to two distinct daughter cells (asymmetric division), Tie2 + CD48 − (HSC) and Tie2 − CD48 + (committed cell), whereas 20% of the cells divided to give rise to two committed Tie2 − CD48 + daughter cells (symmetric division; Fig. 5b) .
To assess the functional robustness of the assay, we investigated the functional asymmetry of the daughter cells after the initial cell division. We performed a functional analysis of paired daughter cells in vitro using an LTC-IC analysis (Fig. 5c) . After an initial division of CD150 + CD48 − CD41 − Flt3 − CD34 − KSL cells, we separated the two daughter cells and analyzed their LTC-IC capacity. Consistent with the phenotyping by Tie2 and CD48 expression, we found functional asymmetry, in which one daughter cell has LTC-IC capacity but the other does not, in more than 40% of the divisions (Fig. 5c) . We confirmed the functional asymmetry of the daughter cells in vivo using BMT assays in which we transplanted each daughter cell into irradiated mice and evaluated its short-and long-term repopulating capacity (Fig. 5d,  Supplementary Fig. 10a and Supplementary Tables 1 and 2) . Notably, the fact that we observed symmetric cell divisions in which both daughter cells had the properties of HSCs in the immunophenotyping assay but not in the in vivo functional assay (Supplementary Table 2) suggests that the production of two long-term HSCs from a parental cell is an infrequent process, although there is potential for its occurrence.
We next investigated the effects of PPAR-δ activation and FAO on the cell-fate decision of dividing HSCs. In CD150 + CD48 − CD41 − Flt3 − CD34 − KSL cells in which Ppard was deleted using retroviral Cre transduction, Ppard-deleted cells had a lower rate of asymmetric division and a higher rate of symmetric commitment (resulting in two committed daughter cells) than did the WT control cells, as assessed using Tie2 and CD48 phenotyping; we found no statistically significant effect of Cre expression alone in these experiments (Fig. 6a,b) . The Ppard-deleted cells also gave rise to paired daughter cells with decreased HSC function in vitro by LTC-IC assay (Fig. 6c) . Treatment with etomoxir similarly decreased asymmetric division and increased symmetric commitment (Fig. 6d,e, Supplementary Fig. 10b and data not shown). In contrast, PPAR-δ activation using GW-501516 increased asymmetric division, an effect that was suppressed by FAO inhibition using etomoxir (Fig. 6f) . A higher dose of etomoxir (20 µM) had a more profound effect than did a lower dose (10 µM) in this experiment, consistent with a differential effect of these two doses on FAO and ATP levels ( Supplementary  Fig. 10c,d) . Treatment with another pharmacological FAO inhibitor, perhexiline, also increased symmetric commitment and counteracted the effect of GW-501516 in promoting asymmetric division ( Supplementary  Fig. 10e,f) . These data implicate PPAR-δ signaling and FAO as central regulators of asymmetric division and HSC fate.
We next tested whether loss of Pml would similarly result in increased symmetric commitment. Indeed, genetic or pharmacological (by treatment with arsenic trioxide) deletion of Pml in CD150 + CD48 − CD41 − Flt3 − CD34 − KSL cells mimicked the loss of Ppard and inhibition of FAO, resulting in reduced asymmetric division and increased symmetric commitment (Fig. 6g and Supplementary Fig. 10g,h) . We confirmed the consequences of the aberrant division pattern induced by Pml deletion in HSCs in vivo (Fig. 6h and Supplementary  Fig. 10i-k) . In agreement with our previous observations that pharmacological activation of PPAR-δ restores the maintenance defect of Pml-deleted HSCs, the defect in asymmetric division of Pml-deleted HSCs was rescued by treatment with the PPAR-δ agonist GW-501516 (Fig. 6i) .
Lastly, we tested whether the observed increase in symmetric commitment could be responsible for the loss of HSC maintenance in vivo caused by deletion of Ppard or Pml. We analyzed the effects of deleting these genes on the fraction of CD48 + cells within the CD34 − KSL cell fraction (Supplementary Fig. 11 ). Consistent with this hypothesis, flow cytometry analysis showed that deletion of Ppard or Pml resulted in an immediate increase in the number of CD34 − KSL cells, with a clear enrichment in the fraction of CD34 − KSL cells that were CD48 + ( Supplemenatry Fig. 11) . Conversely, treatment with GW-501516 decreased the fraction of CD48 + cells within the CD34 − KSL cell compartment of Pml-deleted cells (Supplemenatry Fig. 11a ) but had no effect on Ppard-deleted cells (Supplementary Fig. 11b ). We also found that loss of Pml or Ppard results in exit from quiescence ( Fig. 1g and  Supplementary Figs. 1l, 5i and 7a,b) without induction of apoptosis 16 ( Supplementary Figs. 10k and 12) . Therefore, functional loss along the PML-PPAR-δ-FAO axis triggers a loss of quiescence combined with excessive commitment, resulting in the accumulation of early committed HSCs (CD34 − CD48 + KSL cells) that are unable to sustain the replenishment of the hematopoietic compartment.
DISCUSSION
Our results uncover a crucial metabolic requirement involving PPAR-δ signaling and FAO for preservation of the delicate equilibrium between HSC maintenance and function. These observations are particularly relevant to stem-cell therapy, as both the PPAR-δ pathway and FAO are amenable to pharmacological manipulation. It has been proposed that PPAR activators have beneficial activities in patients with metabolic disorders 38, 39 and are exercise mimetics 15 , which has encouraged the clinical use of this family of compounds. Moreover, selective PPAR-δ activators have undergone phase 1 and 2 clinical trials for the treatment of symptoms related to metabolic disorders, such as obesity and dyslipidemia 40 (NCT00388180 and NCT00158899) ; hence, their safety for human use has been evaluated. The beneficial effects of PPAR-δ activation on HSC function suggest additional clinical applications of PPAR-δ activators for BMT. Notably, although our data highlight a major contribution of FAO downstream of PPAR-δ, we cannot rule out the contribution of additional PPAR-δ-dependent, FAO-independent pathways in HSC maintenance.
We have previously shown that arsenic trioxide, a PML-targeting compound, is highly effective in the induction of cell-cycle entry of quiescent leukemia-initiating cells (LICs) 16 . In accord with our similar findings on the role of PML in regulating PPAR signaling and FAO in breast cancer 35 , Pml-deleted HSCs have defective PPAR-δ-FAO activation. Notably, the HSC maintenance defects caused by Pml deletion npg a r t i c l e s nature medicine VOLUME 18 | NUMBER 9 | SEPTEMBER 2012 1 3 5 7
can be ameliorated by enforcing PPAR-δ activity. Thus, it is tempting to propose that pharmacological inhibitors of FAO may be useful not only for targeting the bulk of leukemic cells 41 but also for promoting LIC exhaustion. However, a careful assessment of the dosing and scheduling of FAO inhibitors would be needed before they can be used in the clinic. As has been described for other LIC-targeting drugs 16 , a combination of these drugs with compounds targeting the proliferating leukemic cell pool is probably required to effectively manage disease. Pharmacological inhibition of the protein mTOR partially rescues the maintenance defect of Pml-deficient HSCs 16 . Interestingly, inhibition of mTOR by rapamycin has been shown to increase FAO in multiple cell types 42, 43 and to activate PPAR signaling 44 , suggesting that PPAR-δ-dependent and mTOR-dependent pathways downstream of PML might converge on the control of FAO and thereby affect HSC maintenance.
It has recently been suggested that hematopoietic cells in mammals can divide asymmetrically as a way to tightly control the decision to selfrenew or differentiate 7, 45 . Our in vitro and in vivo analyses show that the fate of HSCs (maintenance or exhaustion) is accompanied by marked changes in the rate of asymmetric compared to symmetric division. Moreover, we identify PML-PPAR-δ-FAO as the first metabolic pathway to our knowledge that regulates this process, such that impairment of this pathway results in excessive symmetric commitment (Fig. 6j) .
Our findings may also provide a molecular explanation for hematopoietic alterations observed in telomerase-deficient mice 46 and the impaired function of Lkb1-deleted HSCs [20] [21] [22] . In both cases, these defects are accompanied by downregulation of PGC1A expression. Based on our data, these effects may, at least in part, impinge on components of the PML-PGC1A-PPAR-δ pathway, resulting in impaired FAO and symmetric commitment. PML and FAO have been shown to be relevant to sustaining ATP levels when breast epithelial cells lose contact with the extracellular matrix 35, 47 . In an analogous biological process, a functional PML-PPAR-δ-FAO regulatory network may aid in the proper execution of asymmetric HSC division by ensuring adequate ATP production, thereby protecting cells when they lose contact with the bone marrow niche during cell division. Indeed, recent reports support the idea that a decrease in ATP levels is associated with HSC exhaustion 20, 21 . In line with this hypothesis, we found that the PML-PPAR-δ-FAO pathway sustains ATP levels in HSCs. Thus, our data lend support to the notion that fatty acid metabolism downstream of PML and PPAR-δ provides the required energy to allow for the proper execution of asymmetric division, although other mechanisms downstream of PPAR-δ are also probably relevant. Because of current technological limitations, it is not yet feasible to directly image HSC division in vivo, and therefore further studies are warranted for the analysis of this phenomenon in unchallenged HSC in vivo.
In summary, this study uncovers a function for a PML-PPAR-δ-FAO pathway in the control of HSC asymmetric division and maintenance that may open new therapeutic avenues for influencing normal hematopoietic and leukemic stem cell function.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper. a r t i c l e s
